Cost effectiveness of non-drug interventions that reduce nursing home admissions for people living with dementia

Alzheimers Dement. 2023 Sep;19(9):3867-3893. doi: 10.1002/alz.12964. Epub 2023 Apr 6.

Abstract

Introduction: Six million Americans live with Alzheimer's disease and Alzheimer's disease and related dementias (AD/ADRD), a major health-care cost driver. We evaluated the cost effectiveness of non-pharmacologic interventions that reduce nursing home admissions for people living with AD/ADRD.

Methods: We used a person-level microsimulation to model the hazard ratios (HR) on nursing home admission for four evidence-based interventions compared to usual care: Maximizing Independence at Home (MIND), NYU Caregiver (NYU); Alzheimer's and Dementia Care (ADC); and Adult Day Service Plus (ADS Plus). We evaluated societal costs, quality-adjusted life years and incremental cost-effectiveness ratios.

Results: All four interventions cost less and are more effective (i.e., cost savings) than usual care from a societal perspective. Results did not materially change in 1-way, 2-way, structural, and probabilistic sensitivity analyses.

Conclusion: Dementia-care interventions that reduce nursing home admissions save societal costs compared to usual care. Policies should incentivize providers and health systems to implement non-pharmacologic interventions.

Keywords: caregiving; cost effectiveness; dementia; non-drug interventions.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Alzheimer Disease* / therapy
  • Caregivers
  • Cost-Benefit Analysis
  • Cost-Effectiveness Analysis
  • Humans
  • Nursing Homes